Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
The Government of India has issued draft notification G.S.R. 955(E) dated 28 October 2026, proposing amendments to the Drugs Rules, 1945 relating to the release of pharmaceutical product batches for sale and distribution. The draft notification has been published and the govt has invited stakeholder comments and objections before finalization.
The proposed amendments introduce a formal framework for batch release intended to strengthen GMP compliance, batch documentation review, release controls, and accountability across pharmaceutical manufacturing operations
The draft notification proposes:
The proposal introduces a new Rule 68C requiring manufacturers to authorize a suitably qualified and experienced person responsible for batch release in compliance with Schedule M, while maintaining records for each released batch in accordance with Schedule U.
The proposed framework seeks to formalize the review and approval process before a batch is released to the market
The Batch Release Certificate would capture information relating to:
The authorised person shall certify that the batch has been manufactured, tested, reviewed, and approved in accordance with applicable GMP requirements
Strengthening Quality Assurance oversight and enhancing accountability for batch disposition decisions are positive and welcome developments that can improve traceability and oversight of critical product-quality decisions
While the intent of the proposal is appreciated, stakeholders are seeking clarity on certain implementation aspects.
One of the key questions relates to whether the authorised person responsible for batch release will be:
The proposed documentation requirements appear largely aligned with finished pharmaceutical formulations. Additional clarification on applicability and appropriate adaptations for APIs, biological products, vaccines, and other specialised product categories would help ensure consistent implementation and avoid ambiguity
Another important area requiring clarification is the extent of information proposed to be captured within the Batch Release Records and Batch Release Certificate.
The Drugs Rules already require manufacturers to maintain detailed Manufacturing Records and Analytical Records under Schedule U. Similarly, GMP systems established under Schedule M require maintenance of environmental monitoring records, equipment qualification documentation, line clearance records, deviation investigations, change controls, and other supporting quality records
Accordingly, there may be merit in clarifying that the Batch Release Record and Batch Release Certificate are intended to confirm review and acceptability of existing GMP documentation rather than duplicate information already maintained within validated quality systems
A risk-based approach relying on review, certification, and appropriate cross-referencing of existing GMP records may achieve the intended objective of strengthening batch release controls while avoiding unnecessary duplication of documentation.
This will also align the batch release process with internationally recognized GMP principles and quality oversight practices.
Leave a Comment
You must be logged in to post a comment.